Targets › DLK1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2027.
May have a role in neuroendocrine differentiation. (UniProt, P80370)
Open in Phaseline: the race on DLK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chiome Bioscience | CBA-1205 anti-DLK1 monoclonal antibody | DLK1 | Phase 1 | Solid Tumors | Jun 2027 |
Solid Tumors (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.